Form 4: Quince Therapeutics Director Acquires Stock Options in Lieu of Cash Retainer

Director Christopher J. Senner of Quince Therapeutics acquired 35,274 stock options in lieu of his 2025 annual director cash retainer.

Summary

• Christopher J. Senner, a director at Quince Therapeutics, received 35,274 stock options on January 2, 2025.
• These options were granted in place of his annual cash retainer for 2025, as per the company's Outside Director Compensation Policy.
• The options have an exercise price of $1.88 per share and will vest in equal quarterly installments over one year.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, suggesting a positive alignment of interests between the director and the company. The director taking stock instead of cash is a positive sign.

Positives

• The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Management Comments

• The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

Industry Context

It is common for directors of publicly traded companies to receive stock options as part of their compensation package, aligning their interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the biotechnology industry, often used to incentivize long-term value creation.
• The vesting schedule of one year is also typical for director stock options.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock options positively, as it aligns their interests with the company's long-term performance.

Key Dates

Keywords

stock options, director compensation, insider trading, Quince Therapeutics, QNCX, equity